Product
LFG316
1 clinical trial
1 indication
Indication
Paroxysmal Nocturnal HemoglobinuriaClinical trial
An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Completed, Estimated PCD: 2022-05-24